<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Dmannvbs - Latest News</title>
<link href="https://news.prfree.org/rss/dmannvbs/latest.xml"></link>
<updated>2026-07-21T17:54:45+00:00</updated>
<id>urn:uuid:c6c6604c-c936-b332-a8a8-daca479eea73</id>
<entry>
<title>Vascular BioSciences Publishes &quot;CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Model of Pulmonary Hypertension&quot;</title>
<link href="https://news.prfree.org/@dmannvbs/vascular-biosciences-publishes-car-selectively-enhances-the-pulmonary-vasodilatory-effect-of-fasudil-in-a-model-of-pulmonary-hypertension-ui6htp8u2h8e"></link>
<id>urn:uuid:122f4901-0802-5561-df8a-d3927e5cfacc</id>
<summary type="html"><![CDATA[Novel homing peptide enables targeted therapies for pulmonary hypertension]]></summary>
<updated>2023-12-31T07:18:15+00:00</updated>
</entry>
<entry>
<title>Vascular BioSciences Publishes “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy”</title>
<link href="https://news.prfree.org/@dmannvbs/vascular-biosciences-publishes-a-bioinformatic-algorithm-based-on-pulmonary-endoarterial-biopsy-for-targeted-pulmonary-arterial-hypertension-therapy-d6elageyy6vb"></link>
<id>urn:uuid:4550029e-5b2a-1b82-e3b9-0743b6d60938</id>
<summary type="html"><![CDATA[Pioneering approach opens new doors for targeted pulmonary arterial hypertension therapy]]></summary>
<updated>2023-12-31T07:04:06+00:00</updated>
</entry>
<entry>
<title>Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide</title>
<link href="https://news.prfree.org/@dmannvbs/vascular-biosciences-announces-new-preclinical-research-results-demonstrating-improved-pulmonary-hypertension-and-sepsis-survival-with-car-peptide-3rm6qjb7rkeq"></link>
<id>urn:uuid:efaefcdb-0af4-c262-d3e0-6a4bc2f1c863</id>
<summary type="html"><![CDATA[CEO of Vascular BioSciences, David Mann, makes connection between current research and COVID-19 applications]]></summary>
<updated>2020-06-04T04:27:45+00:00</updated>
</entry>
<entry>
<title>FDA Grants Vascular BioSciences HUD Designation to the Endoarterial Biopsy Catheter for Group 1 PAH</title>
<link href="https://news.prfree.org/@dmannvbs/fda-grants-vascular-biosciences-hud-designation-to-the-endoarterial-biopsy-catheter-for-group-1-pah-qak74e3dymy3"></link>
<id>urn:uuid:a1ec35dc-3280-4ed4-a89c-8df30df0c495</id>
<summary type="html"><![CDATA[VBS received HUD designation from FDA for EABx Catheter to take pulmonary artery biopsies in PAH patients.]]></summary>
<updated>2019-09-06T19:14:50+00:00</updated>
</entry>
<entry>
<title>Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI</title>
<link href="https://news.prfree.org/@dmannvbs/vascular-biosciences-awarded-2-million-phase-ii-sttr-grant-from-nhlbi-b7kxqdnx6mry"></link>
<id>urn:uuid:c78f138b-150e-df0b-2820-894ecf1248df</id>
<summary type="html"><![CDATA[Grant awarded in partnership with Brigham and Women’s Hospital, Harvard Medical School to develop CAR peptide as a targeted therapy for pulmonary hypertension]]></summary>
<updated>2018-10-19T17:34:05+00:00</updated>
</entry>
</feed>